ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
Turnover
60.53%
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+12.16%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$188M
AUM Growth
+$22M
(+13%)
Cap. Flow
+$15.2M
Cap. Flow
% of AUM
8.05%
Top 10 Holdings %
Top 10 Hldgs %
64.3%
Holding
38
New
9
Increased
8
Reduced
7
Closed
14
Avg Time Held
0.4
years
Top 10 Avg Time Held
0
years
Top 20 Avg Time Held
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$14.7M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$12.3M |
| 3 |
UnitedHealth
UNH
|
+$12.2M |
| 4 |
IQVIA
IQV
|
+$11.5M |
| 5 |
AbbVie
ABBV
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alkermes
ALKS
|
+$11.5M |
| 2 |
Medtronic
MDT
|
+$10.5M |
| 3 |
Insulet
PODD
|
+$10.4M |
| 4 |
Hologic
HOLX
|
+$10.3M |
| 5 |
Sage Therapeutics
SAGE
|
+$10.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.63% |
| 2 | Financials | 0.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Avalo Therapeutics
AVTX
$635M
| – | – |
-186
| Closed | -$1.17M | – |
|
27
AstraZeneca
AZN
$251B
| – | – |
-58,121
| Closed | -$6.98M | – |
|
28
Baxter International
BAX
$12.8B
| – | – |
-61,570
| Closed | -$4.95M | – |
|
|
29
DELISTED
Hologic
HOLX
| – | – |
-138,884
| Closed | -$10.3M | – |
|
30
Disc Medicine
IRON
$2.14B
| – | – |
-9,469
| Closed | -$1.15M | – |
|
31
Kymera Therapeutics
KYMR
$8.88B
| – | – |
-89,071
| Closed | -$5.23M | – |
|
32
Larimar Therapeutics
LRMR
$217M
| – | – |
-34,943
| Closed | -$403K | – |
|
|
33
Medtronic
MDT
$121B
| – | – |
-83,737
| Closed | -$10.5M | – |
|
|
34
Insulet
PODD
$9.29B
| – | – |
-36,732
| Closed | -$10.4M | – |
|
35
PTC Therapeutics
PTCT
$4.98B
| – | – |
-215,985
| Closed | -$8.04M | – |
|
|
RNAM
36
DELISTED
Avidity Biosciences
RNAM
| – | – |
-126,116
| Closed | -$3.11M | – |
|
|
37
DELISTED
Sage Therapeutics
SAGE
| – | – |
-229,117
| Closed | -$10.2M | – |
|
|
ARNA
38
DELISTED
Arena Pharmaceuticals Inc
ARNA
| – | – |
-150,001
| Closed | -$8.93M | – |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q4 2021 Portfolio in Review
As of Q4 2021, Asymmetry Capital Management held 38 positions worth $188M, up 13% from $166M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Asymmetry Capital Management deployed $15.2M of net new capital in Q4 2021, opening 9 new positions and adding to 8 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 177,741 shares worth $15.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was DICE Therapeutics, Inc. Common Stock, an estimated $2.64M trimmed.
- Asymmetry Capital Management's largest Q4 2021 buy was BioMarin Pharmaceuticals: 177,741 shares worth $15.7M.
- Asymmetry Capital Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021, an estimated $12.3M increase.
- Asymmetry Capital Management's biggest Q4 2021 reduction was DICE Therapeutics, Inc. Common Stock, cutting an estimated $2.64M.
- Asymmetry Capital Management fully exited Alkermes in Q4 2021, selling an estimated $11.5M.
- Asymmetry Capital Management's ten largest holdings make up 64% of its $188M portfolio in Q4 2021.
- Asymmetry Capital Management opened 9 new positions and closed 14 in Q4 2021.
- Asymmetry Capital Management's portfolio value rose 13% quarter-over-quarter to $188M.
Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.